FrancophonIA/ELRC3.0 huggingface dataset:
English: Oprymea 0.52 mg: Each prolonged-release tablet contains 0.52 mg pramipexole (as 0.75 mg pramipexole dihydrochloride monohydrate).
Swedish: Oprymea 0,52 mg: Varje depottablett innehåller 0,52 mg pramipexol (vilket motsvarar 0,75 mg pramipexoldihydrokloridmonohydrat).
English: - Vision impairment.
Swedish: - synstörning.
English: Each prolonged-release tablet contains 2.62 mg pramipexole (as 3.75 mg pramipexole dihydrochloride monohydrate).
Swedish: Varje depottablett innehåller 2,62 mg pramipexol (vilket motsvarar 3,75 mg pramipexoldihydrokloridmonohydrat).
English: Oprymea 0.26 mg Oprymea 0.52 mg Oprymea 1.05 mg prolonged-release tablets
Swedish: Oprymea 0,26 mg Oprymea 0,52 mg Oprymea 1,05 mg depottabletter
English: If you have advanced Parkinson's disease and are also taking levodopa, you might develop dyskinesia during the uptitration of Oprymea - Dystonia (inability of keeping your body and neck straight and upright (axial dystonia)).
Swedish: Om du har avancerad Parkinsons sjukdom och även tar levodopa, kan du utveckla dyskinesi under upptitreringsperioden med Oprymea.
English: - Sleepiness and episodes of suddenly falling asleep - Psychosis (e.g. comparable with symptoms of schizophrenia) - Vision impairment.
Swedish: - psykos (t ex jämförbart med symtom på schizofreni).
English: Oprymea 0.26 mg Oprymea 0.52 mg Oprymea 1.05 mg prolonged-release tablets Pramipexole
Swedish: Oprymea 0,26 mg Oprymea 0,52 mg Oprymea 1,05 mg depottabletter Pramipexol
English: Ascending dose schedule of Oprymea prolonged-release tablets Week Daily dose (mg of base)
Swedish: Schema för dosökning med Oprymea depottabletter Vecka Dygnsdos (mg bas) Dygnsdos (mg salt)
English: Oprymea 2.62 mg prolonged-release tablets
Swedish: Oprymea 2,62 mg depottabletter
English: Each tablet contains 1.1 mg pramipexole (as 1.5 mg pramipexole dihydrochloride monohydrate).
Swedish: Varje tablett innehåller 1,1 mg pramipexol (vilket motsvarar 1,5 mg pramipexoldihydrokloridmonohydrat).
English: 2 tablets Oprymea 0.18 mg
Swedish: 2 tabletter Oprymea 0,18 mg eller
English: 0.26 mg: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots.
Swedish: 0,26 mg: Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P1 på ena sidan, med fasade kanter och eventuella fläckar.
English: 1.05 mg: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots.
Swedish: 1,05 mg: Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P3 på ena sidan, med fasade kanter och eventuella fläckar.
English: Oprymea 1.1 mg tablets 20 tablets: EU/1/08/469/021 30 tablets: EU/1/08/469/022 60 tablets: EU/1/08/469/023 90 tablets: EU/1/08/469/024 100 tablets: EU/1/08/469/025
Swedish: Oprymea 1,1 mg tabletter 20 tabletter: EU/1/08/469/021 30 tabletter: EU/1/08/469/022 60 tabletter: EU/1/08/469/023 90 tabletter: EU/1/08/469/024 100 tabletter: EU/1/08/469/025
English: The daily dose is administered in equally divided doses 3 times a day.
Swedish: Parkinsons sjukdom Dygnsdosen administreras fördelad på 3 lika doser.
English: What Oprymea looks like and contents of the pack Oprymea 0.26 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots.
Swedish: Läkemedlets utseende och förpackningsstorlekar Oprymea 0,26 mg depottabletter är vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P1 på ena sidan, med fasade kanter och eventuella fläckar.
English: Each prolonged-release tablet contains 1.57 mg pramipexole (as 2.25 mg pramipexole dihydrochloride monohydrate).
Swedish: Varje depottablett innehåller 1,57 mg pramipexol (vilket motsvarar 2,25 mg pramipexoldihydrokloridmonohydrat).
English: Oprymea 3.15 mg prolonged-release tablets
Swedish: Oprymea 3,15 mg depottabletter
English: Each prolonged-release tablet contains 3.15 mg pramipexole (as 4.5 mg pramipexole dihydrochloride monohydrate).
Swedish: Varje depottablett innehåller 3,15 mg pramipexol (vilket motsvarar 4,5 mg pramipexoldihydrokloridmonohydrat).
English: Each tablet contains 0.35 mg pramipexole (as 0.5 mg pramipexole dihydrochloride monohydrate).
Swedish: Varje tablett innehåller 0,35 mg pramipexol (vilket motsvarar 0,5 mg pramipexoldihydrokloridmonohydrat).
English: 0.52 mg: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Swedish: 0,52 mg: Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P2 på ena sidan, med fasade kanter och eventuella fläckar.
English: Oprymea 3.15 mg prolonged-release tablets Pramipexole
Swedish: Oprymea 3,15 mg depottabletter Pramipexol
English: Each tablet contains 0.18 mg pramipexole (as 0.25 mg pramipexole dihydrochloride monohydrate).
Swedish: Varje tablett innehåller 0,18 mg pramipexol (vilket motsvarar 0,25 mg pramipexoldihydrokloridmonohydrat).
English: Oprymea 0.35 mg tablets 20 tablets: EU/1/08/469/011 30 tablets: EU/1/08/469/012 60 tablets: EU/1/08/469/013 90 tablets: EU/1/08/469/014 100 tablets: EU/1/08/469/015
Swedish: Oprymea 0,35 mg tabletter 20 tabletter: EU/1/08/469/011 30 tabletter: EU/1/08/469/012 60 tabletter: EU/1/08/469/013 90 tabletter: EU/1/08/469/014
English: Each tablet contains 0.7 mg pramipexole (as 1 mg pramipexole dihydrochloride monohydrate).
Swedish: Varje tablett innehåller 0,7 mg pramipexol (vilket motsvarar 1 mg pramipexoldihydrokloridmonohydrat).
English: EU/1/08/469/011 [20 tablets] EU/1/08/469/012 [30 tablets] EU/1/08/469/013 [60 tablets] EU/1/08/469/014 [90 tablets] EU/1/08/469/015 [100 tablets]
Swedish: EU/1/08/469/011 [20 tabletter] EU/1/08/469/012 [30 tabletter] EU/1/08/469/013 [60 tabletter] EU/1/08/469/014 [90 tabletter] EU/1/08/469/015 [100 tabletter]
English: EU/1/08/469/021 [20 tablets] EU/1/08/469/022 [30 tablets] EU/1/08/469/023 [60 tablets] EU/1/08/469/024 [90 tablets] EU/1/08/469/025 [100 tablets]
Swedish: EU/1/08/469/021 [20 tabletter] EU/1/08/469/022 [30 tabletter] EU/1/08/469/023 [60 tabletter] EU/1/08/469/024 [90 tabletter] EU/1/08/469/025 [100 tabletter]
English: Oprymea 0.18 mg tablets 20 tablets: EU/1/08/469/006 30 tablets: EU/1/08/469/007 60 tablets: EU/1/08/469/008 90 tablets: EU/1/08/469/009 100 tablets: EU/1/08/469/010
Swedish: Oprymea 0,18 mg tabletter 20 tabletter: EU/1/08/469/006 30 tabletter: EU/1/08/469/007 60 tabletter: EU/1/08/469/008 90 tabletter: EU/1/08/469/009 100 tabletter: EU/1/08/469/010
English: Oprymea 3.15 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/050 30 prolonged-release tablets: EU/1/08/469/051 90 prolonged-release tablets: EU/1/08/469/052 100 prolonged-release tablets: EU/1/08/469/053
Swedish: Oprymea 3,15 mg depottabletter 10 depottabletter: EU/1/08/469/050 30 depottabletter: EU/1/08/469/051 90 depottabletter: EU/1/08/469/052 100 depottabletter: EU/1/08/469/053
English: Each prolonged-release tablet contains 1.05 mg pramipexole (as 1.5 mg pramipexole dihydrochloride monohydrate).
Swedish: Varje depottablett innehåller 1,05 mg pramipexol (vilket motsvarar 1,5 mg pramipexoldihydrokloridmonohydrat).
English: Each prolonged-release tablet contains 2.1 mg pramipexole (as 3 mg pramipexole dihydrochloride monohydrate).
Swedish: Varje depottablett innehåller 2,1 mg pramipexol (vilket motsvarar 3 mg pramipexoldihydrokloridmonohydrat).
English: Oprymea 2.1 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P4 on one side, with bevelled edges and possible spots.
Swedish: Oprymea 2,1 mg depottabletter är vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P4 på ena sidan, med fasade kanter och eventuella fläckar.
English: Oprymea 0.7 mg tablets 20 tablets: EU/1/08/469/016 30 tablets: EU/1/08/469/017 60 tablets: EU/1/08/469/018 90 tablets: EU/1/08/469/019 100 tablets: EU/1/08/469/020
Swedish: Oprymea 0,7 mg tabletter 20 tabletter: EU/1/08/469/016 30 tabletter: EU/1/08/469/017 60 tabletter: EU/1/08/469/018 90 tabletter: EU/1/08/469/019 100 tabletter: EU/1/08/469/020
English: Oprymea 1.05 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/034 30 prolonged-release tablets: EU/1/08/469/035 90 prolonged-release tablets: EU/1/08/469/036 100 prolonged-release tablets: EU/1/08/469/037
Swedish: Oprymea 1,05 mg depottabletter 10 depottabletter: EU/1/08/469/034 30 depottabletter: EU/1/08/469/035 90 depottabletter: EU/1/08/469/036 100 depottabletter: EU/1/08/469/037
English: Oprymea 1.05 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots.
Swedish: Oprymea 1,05 mg depottabletter är vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P3 på ena sidan, med fasade kanter och eventuella fläckar.
English: Oprymea 1.05 mg prolonged-release tablets
Swedish: Oprymea 1,05 mg depottabletter
English: Oprymea 1.57 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P12 on one side, with bevelled edges and possible spots.
Swedish: Oprymea 1,57 mg depottabletter är vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P12 på ena sidan, med fasade kanter och eventuella fläckar.
English: Nervous system disorders headache dizziness somnolance sudden onset of sleep syncope dyskinesia amnesia hyperkinesia
Swedish: Centrala och perifera nervsystemet somnolens yrsel dyskinesi huvudvärk plötsligt insomnande minnesförlustamnesi hyperkinesi synkope
English: patients with Parkinson's Disease treated with pramipexole.
Swedish: Klinisk effekt och säkerhet vid Parkinsons sjukdom Hos patienter leder behandling med pramipexol till symtomförbättring vid idiopatisk Parkinsons sjukdom.
English: Oprymea 2.1 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/042 30 prolonged-release tablets: EU/1/08/469/043 90 prolonged-release tablets: EU/1/08/469/044 100 prolonged-release tablets: EU/1/08/469/045
Swedish: Oprymea 2,1 mg depottabletter 10 depottabletter: EU/1/08/469/042 30 depottabletter: EU/1/08/469/043 90 depottabletter: EU/1/08/469/044 100 depottabletter: EU/1/08/469/045
English: EU/1/08/469/001[20 tablets] EU/1/08/469/002 [30 tablets] EU/1/08/469/003 [60 tablets] EU/1/08/469/004 [90 tablets] EU/1/08/469/005 [100 tablets]
Swedish: EU/1/08/469/001 [20 tabletter] EU/1/08/469/002 [30 tabletter] EU/1/08/469/003 [60 tabletter] EU/1/08/469/004 [90 tabletter] EU/1/08/469/005 [100 tabletter]
English: EU/1/08/469/016 [20 tablets] EU/1/08/469/017 [30 tablets] EU/1/08/469/018 [60 tablets] EU/1/08/469/019 [90 tablets] EU/1/08/469/020 [100 tablets]
Swedish: EU/1/08/469/016 [20 tabletter] EU/1/08/469/017 [30 tabletter] EU/1/08/469/018 [60 tabletter] EU/1/08/469/019 [90 tabletter] EU/1/08/469/020 [100 tabletter]
English: Oprymea 2.62 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/046 30 prolonged-release tablets: EU/1/08/469/047 90 prolonged-release tablets: EU/1/08/469/048 100 prolonged-release tablets: EU/1/08/469/049
Swedish: Oprymea 2,62 mg depottabletter 10 depottabletter: EU/1/08/469/046 30 depottabletter: EU/1/08/469/047 90 depottabletter: EU/1/08/469/048 100 depottabletter: EU/1/08/469/049
English: EU/1/08/469/042 [10 prolonged-release tablets] EU/1/08/469/043 [30 prolonged-release tablets] EU/1/08/469/044 [90 prolonged-release tablets] EU/1/08/469/045 [100 prolonged-release tablets]
Swedish: EU/1/08/469/042 [10 depottabletter] EU/1/08/469/043 [30 depottabletter] EU/1/08/469/044 [90 depottabletter] EU/1/08/469/045 [100 depottabletter]
English: Oprymea 0.52 mg prolonged-release tablets are white or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Swedish: Oprymea 0,52 mg depottabletter är vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P2 på ena sidan, med fasade kanter och eventuella fläckar.
English: Oprymea 1.57 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/038 30 prolonged-release tablets: EU/1/08/469/039 90 prolonged-release tablets: EU/1/08/469/040 100 prolonged-release tablets: EU/1/08/469/041
Swedish: Oprymea 1,57 mg depottabletter 10 depottabletter: EU/1/08/469/038 30 depottabletter: EU/1/08/469/039 90 depottabletter: EU/1/08/469/040 100 depottabletter: EU/1/08/469/041
English: Oprymea 1.57 mg prolonged-release tablets
Swedish: Oprymea 1,57 mg depottabletter
English: Tell your doctor if you have or have had or develop any medical conditions or symptoms, especially any of the following: - Kidney disease - Hallucinations (seeing, hearing or feeling things that are not there).
Swedish: Tala om för din läkare om du har (har haft) eller fått några symtom, speciellt något av följande: njursjukdom.
English: EU/1/08/469/050 [10 prolonged-release tablets] EU/1/08/469/051 [30 prolonged-release tablets] EU/1/08/469/052 [90 prolonged-release tablets] EU/1/08/469/053 [100 prolonged-release tablets]
Swedish: EU/1/08/469/050 [10 depottabletter] EU/1/08/469/051 [30 depottabletter] EU/1/08/469/052 [90 depottabletter] EU/1/08/469/053 [100 depottabletter]
English: EU/1/08/469/006 [20 tablets] EU/1/08/469/007 [30 tablets] EU/1/08/469/008 [60 tablets] EU/1/08/469/009 [90 tablets] EU/1/08/469/010 [100 tablets]
Swedish: EU/1/08/469/006 [20 tabletter] EU/1/08/469/007 [30 tabletter] EU/1/08/469/008 [60 tabletter] EU/1/08/469/009 [90 tabletter] EU/1/08/469/010 [100 tabletter]
English: EU/1/08/469/034 [10 prolonged-release tablets] EU/1/08/469/035 [30 prolonged-release tablets] EU/1/08/469/036 [90 prolonged-release tablets] EU/1/08/469/037 [100 prolonged-release tablets]
Swedish: EU/1/08/469/034 [10 depottabletter] EU/1/08/469/035 [30 depottabletter] EU/1/08/469/036 [90 depottabletter] EU/1/08/469/037 [100 depottabletter]
English: EU/1/08/469/046 [10 prolonged-release tablets] EU/1/08/469/047 [30 prolonged-release tablets] EU/1/08/469/048 [90 prolonged-release tablets] EU/1/08/469/049 [100 prolonged-release tablets]
Swedish: EU/1/08/469/046 [10 depottabletter] EU/1/08/469/047 [30 depottabletter] EU/1/08/469/048 [90 depottabletter] EU/1/08/469/049 [100 depottabletter]
English: Oprymea 0.52 mg prolonged-release tablets Pramipexole
Swedish: Oprymea 0,52 mg depottabletter Pramipexol
English: Each prolonged-release tablet contains 0.26 mg pramipexole (as 0.375 mg pramipexole dihydrochloride monohydrate).
Swedish: Varje depottablett innehåller 0,26 mg pramipexol (vilket motsvarar 0,375 mg pramipexoldihydrokloridmonohydrat).
English: Oprymea 1.57 mg prolonged-release tablets Pramipexole
Swedish: Oprymea 1,57 mg depottabletter Pramipexol
English: One Oprymea 0.26 mg prolonged-release tablet on blister "Week 1".
Swedish: Dosökningsschema för Oprymea depottabletter Vecka Dygnsdos (mg) Antal tabletter En Oprymea 0,26 mg depottablett från blister ”Vecka 1”.
English: Oprymea 0.26 mg prolonged-release tablets 10 prolonged-release tablets: EU/1/08/469/026 30 prolonged-release tablets: EU/1/08/469/027 90 prolonged-release tablets: EU/1/08/469/028 100 prolonged-release tablets: EU/1/08/469/029
Swedish: Oprymea 0,26 mg depottabletter 10 depottabletter: EU/1/08/469/026 30 depottabletter: EU/1/08/469/027 90 depottabletter: EU/1/08/469/028 100 depottabletter: EU/1/08/469/029
English: Oprymea 0.52 mg prolonged-release tablets
Swedish: Oprymea 0,52 mg depottabletter
English: EU/1/08/469/030 [10 prolonged-release tablets] EU/1/08/469/031[30 prolonged-release tablets] EU/1/08/469/032[90 prolonged-release tablets] EU/1/08/469/033[100 prolonged-release tablets]
Swedish: EU/1/08/469/030 [10 depottabletter] EU/1/08/469/031 [30 depottabletter] EU/1/08/469/032 [90 depottabletter] EU/1/08/469/033 [100 depottabletter]
English: Oprymea 1.05 mg prolonged-release tablets Pramipexole
Swedish: Oprymea 1,05 mg depottabletter Pramipexol
English: Oprymea 2.1 mg prolonged-release tablets Pramipexole
Swedish: Oprymea 2,1 mg depottabletter Pramipexol
English: EU/1/08/469/038 [10 prolonged-release tablets] EU/1/08/469/039 [30 prolonged-release tablets] EU/1/08/469/040 [90 prolonged-release tablets] EU/1/08/469/041 [100 prolonged-release tablets]
Swedish: EU/1/08/469/038 [10 depottabletter] EU/1/08/469/039 [30 depottabletter] EU/1/08/469/040 [90 depottabletter] EU/1/08/469/041 [100 depottabletter]
English: Each prolonged-release tablet contains 0.52 mg pramipexole (as 0.75 mg pramipexole dihydrochloride monohydrate).
Swedish: Varje depottablett innehåller 0,52 mg pramipexol (vilket motsvarar 0,75 mg pramipexoldihydrokloridmonohydrat).
English: st week
Swedish: Första veckan
English: Very rare may affect up to 1 in 10,000 people
Swedish: Mindre vanliga: kan förekomma hos upp till 1 av 100 användare Sällsynta:
English: EU/1/08/469/026 [10 prolonged-release tablets] EU/1/08/469/027 [30 prolonged-release tablets] EU/1/08/469/028 [90 prolonged-release tablets] EU/1/08/469/029 [100 prolonged-release tablets]
Swedish: EU/1/08/469/026 [10 depottabletter] EU/1/08/469/027 [30 depottabletter] EU/1/08/469/028 [90 depottabletter] EU/1/08/469/029 [100 depottabletter]
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P3 on one side, with bevelled edges and possible spots.
Swedish: Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P3 på ena sidan, med fasade kanter och eventuella fläckar.
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P1 on one side, with bevelled edges and possible spots.
Swedish: Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P1 på ena sidan, med fasade kanter och eventuella fläckar.
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P12 on one side, with bevelled edges and possible spots.
Swedish: Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P12 på ena sidan, med fasade kanter och eventuella fläckar.
English: - 7 prolonged-release tablets of 1.05 mg
Swedish: - 7 stycken 1,05 mg depottabletter
English: Do not chew, divide or crush the prolonged-release tablets.
Swedish: Depottabletten får inte tuggas, delas eller krossas.
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P4 on one side, with bevelled edges and possible spots.
Swedish: Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P4 på ena sidan, med fasade kanter och eventuella fläckar.
English: Oprymea 0.26 mg prolonged-release tablets Pramipexole
Swedish: Oprymea 0,26 mg depottabletter Pramipexol
English: Breast-feeding
Swedish: BLISTERKARTONG
English: Oprymea 2.1 mg prolonged-release tablets
Swedish: Oprymea 2,1 mg depottabletter
English: White or almost white, round (diameter 10 mm), slightly biconvex tablets engraved with P2 on one side, with bevelled edges and possible spots.
Swedish: Vita eller nästan vita, runda (diameter 10 mm), svagt bikonvexa tabletter märkta med P2 på ena sidan, med fasade kanter och eventuella fläckar.
English: Oprymea 0.26 mg prolonged-release tablets
Swedish: Oprymea 0,26 mg depottabletter
English: Oprymea 0.26 mg prolonged-release tablets Oprymea 0.52 mg prolonged-release tablets Oprymea 1.05 mg prolonged-release tablets
Swedish: Oprymea 0,26 mg depottabletter Oprymea 0,52 mg depottabletter Oprymea 1,05 mg depottabletter
English: Further information on Viread can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/viread.
Swedish: Mer information om Viread finns på EMA:s webbplats ema.europa.eu/medicines/human/EPAR/viread.
English: What measures are being taken to ensure the safe and effective use of Viread?
Swedish: Vad görs för att garantera säker och effektiv användning av Viread?
English: What is Viread and what is it used for?
Swedish: Vad är Viread och vad används det för?
English: Viread received a marketing authorisation valid throughout the EU on 5 February 2002.
Swedish: Den 5 februari 2002 beviljades Viread ett godkännande för försäljning som gäller i hela EU.
English: Rare cases of severe kidney problems have also been seen in patients treated with Viread.
Swedish: Sällsynta fall av allvarliga njurproblem har också setts hos patienter som behandlats med Viread.
English: Side effects reported with Viread are carefully evaluated and any necessary action taken to protect patients.
Swedish: Biverkningar som har rapporterats för Viread utvärderas noggrant och nödvändiga åtgärder vidtas för att skydda patienterna.
English: Why is Viread authorised in the EU?
Swedish: Varför är Viread godkänt i EU?
English: What benefits of Viread have been shown in studies?
Swedish: Vilka fördelar med Viread har visats i studierna?
English: The European Medicines Agency decided that Viread's benefits are greater than its risks and it can be authorised for use in the EU.
Swedish: Europeiska läkemedelsmyndigheten (EMA) fann att fördelarna med Viread är större än riskerna och att läkemedlet kan godkännas för försäljning i EU.
English: Viread, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Swedish: Viread, som tas i kombination med andra antivirala läkemedel, minskar mängden hiv i blodet och håller den på en låg nivå.
English: An overview of Viread and why it is authorised in the EU
Swedish: Sammanfattning av Viread och varför det är godkänt inom EU
English: As for all medicines, data on the use of Viread are continuously monitored.
Swedish: Liksom för alla läkemedel övervakas de vetenskapliga uppgifterna för Viread kontinuerligt.
English: Moreover, Viread may cause a reduction in bone density.
Swedish: Viread kan även orsaka minskad bentäthet.
English: Although it showed no benefit of adding Viread to existing treatment compared with adding placebo, Viread produced similar levels of the active substance in the body compared to adults, and it was judged that the results were influenced by the type of patients included in the Viread group.
Swedish: Även om man inte såg någon nytta med att lägga till Viread till den befintliga behandlingen jämfört med att lägga till placebo, ledde Viread till liknande nivåer av den aktiva substansen i kroppen som hos vuxna, och man bedömde att resultaten påverkades av typen av patienter som ingick i Vireadgruppen.
English: Viread does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Swedish: Viread botar inte hivinfektionen eller aids men kan fördröja skadan på immunsystemet och utvecklingen av infektioner och sjukdomar som är kopplade till aids.
English: For the treatment of HIV, Viread was more effective than placebo (a dummy treatment) when added to existing treatment.
Swedish: För behandling mot hiv var Viread effektivare än placebo (overksam behandling) när det lades till den befintliga behandlingen.
English: Viread (tenofovir disoproxil)
Swedish: Viread (tenofovirdisoproxil)
English: The company that makes Viread will ensure that all doctors who are expected to prescribe or use Viread in children are provided with educational materials containing important safety information, particularly on the risks and precautions relating to kidney function and the bones.
Swedish: Företaget som marknadsför Viread kommer att se till att alla läkare som väntas förskriva eller ge Viread till barn får utbildningsmaterial som innehåller viktig säkerhetsinformation, särskilt om riskerna och försiktighetsåtgärderna som rör njurfunktion och skelett.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Viread have also been included in the summary of product characteristics and the package leaflet.
Swedish: Rekommendationer och försiktighetsåtgärder som hälso- och sjukvårdpersonal och patienter ska iaktta för säker och effektiv användning av Viread har också tagits med i produktresumén och bipacksedeln.